# HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015

Andrew Atkinson, David Kraus, Nicolas Banholzer, Jose M Miro, Peter Reiss, Ole Kirk, Cristina Mussini, Philippe Morlat, Daria Podlekareva, Alison D Grant, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Andrew Atkinson, David Kraus, Nicolas Banholzer, Jose M Miro, Peter Reiss, et al.. HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983-2015. PLoS ONE, 2024, 19 (10), pp.e0312035. 10.1371/journal.pone.0312035 . hal-04793909

HAL Id: hal-04793909

https://hal.science/hal-04793909v1

Submitted on 20 Nov 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>
RESEARCH ARTICLE

# HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983–2015

Andrew Atkinson<sup>1,2,3*</sup>, David Kraus<sup>1,2,4*</sup>, Nicolas Banholzer<sup>1</sup>, Jose M. Miro<sup>1,5,6</sup>, Peter Reiss<sup>1,7,8</sup>, Ole Kirk<sup>9,10</sup>, Cristina Mussini<sup>11</sup>, Philippe Morlat<sup>12,13</sup>, Daria Podlekareva<sup>9,14</sup>, Alison D. Grant<sup>15,16</sup>, Caroline Sabin<sup>17</sup>, Marc van der Valk<sup>17,8,18</sup>, Vincent Le Moing<sup>19</sup>, Laurence Meyer<sup>20</sup>, Remonie Seng<sup>20</sup>, Antonella Castagna<sup>21</sup>, Niels Obel<sup>10</sup>, Anastasia Antoniadou<sup>22</sup>, Dominique Salmon<sup>23</sup>, Marcel Zwahlen<sup>1</sup>, Matthias Egger<sup>1,24,25</sup>, Stephane de Wit<sup>26</sup>, Hansjakob Furrer<sup>2‡</sup>, Lukas Fenner<sup>1*#</sup>, The Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord<sup>¶</sup>

<figure><img src="image_3.png" /></figure>

1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, 2 Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland, 3 Infectious Diseases Division, Washington University School of Medicine in St Louis, St Louis, MO, United States of America, 4 Department of Mathematics and Statistics, Masaryk University, Brno, Czech Republic, 5 Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain, 6 CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain, 7 Stichting HIV Monitoring, Amsterdam, The Netherlands, 8 Amsterdam UMC, location University of Amsterdam, Global Health, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands, 9 Centre of Excellence for Health, Immunity and Infections (CHIP), Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 10 Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 11 Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, 12 ISPED, INSERM Bordeaux Population Health Research Center, Team PHARes, UMR 1219, University of Bordeaux, Bordeaux, France, 13 Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bordeaux (CHU), Bordeaux, France, 14 Department of Respiratory and Infectious Diseases, Copenhagen University Hospital, Bispebjerg, Denmark, 15 Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom, 16 Africa Health Research Institute, School of Laboratory Medicine & Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, KwaZulu-Natal, South Africa, 17 Institute for Global Health, University College London, London, United Kingdom, 18 Department of Infectious Diseases, Location University of Amsterdam, Amsterdam Institute for Immunology & Infectious Diseases, Infectious Diseases Program, Amsterdam UMC, Amsterdam, The Netherlands, 19 CHU de Montpellier, Université de Montpellier, Montpellier, France, 20 Department of Public Health and Epidemiology, AP-HP, Bicêtre Hospital, INSERM CESP U1018, Paris-Saclay University, Le Kremlin Bicêtre, France, 21 Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy, 22 University General Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 23 Department of Infectious Diseases, Institut Fournier, Paris, France, 24 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom, 25 Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, 26 Department of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium

© These authors contributed equally to this work.

‡ HF and LF also contributed equally to this work.

¶ The complete membership of the collaboration can be found in the Acknowledgments.

* lukas.fenner@unibe.ch

<figure><img src="image_4.png" /></figure>

OPEN ACCESS

**Citation:** Atkinson A, Kraus D, Banholzer N, Miro JM, Reiss P, Kirk O, et al. (2024) HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983–2015. PLoS ONE 19(10): e0312035. https://doi.org/10.1371/journal.pone.0312035

**Editor:** Maemu Petronella Gededzha, University of the Witwatersrand, SOUTH AFRICA

**Received:** April 17, 2024

**Accepted:** September 30, 2024

**Published:** October 25, 2024

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0312035

**Copyright:** © 2024 Atkinson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data used for the analysis will generally not be publicly available for ethical and legal reasons but can be made available based on the approval by the chair of the executive
committee of COHERE (contact: christine.schwimmer@u-bordeaux.fr).

**Funding:** The COHERE study group has received unrestricted funding from: Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Denmark. COHERE received funding from the European Union Seventh Framework Programme [grant no. FP7/2007–2013] under EuroCoord grant agreement no. 260694. Research reported in this publication was supported by the Swiss National Science Foundation [grant no. 324730_149792]. AA and DK were supported by the Swiss National Science Foundation [grant no. 324730_149792]. NB, ME, and LF are supported by the National Institute of Allergy and Infectious Diseases (NIAID) through grant no. 5U01-AI069924-05. ME is supported by special project funding from the Swiss National Science Foundation [grant no. 32FP30-189498]. JMM received a personal 80:20 research grant from Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–24. All other authors report no competing interests. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

**Competing interests:** The authors have declared that no competing interests exist.

# Abstract

## Introduction

HIV replication leads to a change in lymphocyte phenotypes that impairs immune protection against opportunistic infections. We examined current HIV replication as an independent risk factor for tuberculosis (TB).

## Methods

We included people living with HIV from 25 European cohorts 1983–2015. Individuals <16 years or with previous TB were excluded. Person-time was calculated from enrolment (baseline) to the date of TB diagnosis or last follow-up information. We used adjusted Poisson regression and general additive regression models.

## Results

We included 272,548 people with a median follow-up of 5.9 years (interquartile range [IQR] 2.3–10.9). At baseline, the median CD4 cell count was 355 cells/µL (IQR 193–540) and the median HIV-RNA level 22,000 copies/mL (IQR 1,300–103,000). During 1,923,441 person-years of follow-up, 5,956 (2.2%) people developed TB. Overall, TB incidence was 3.1 per 1,000 person-years (95% confidence interval [CI] 3.02–3.18) and was four times higher in patients with HIV-RNA levels of 10,000 compared with levels <400 copies/mL in any CD4 stratum. CD4 and HIV-RNA time-updated analyses showed that the association between HIV-RNA and TB incidence was independent of CD4. The TB incidence rate ratio for people born in TB-endemic countries compared with those born in Europe was 1.8 (95% CI 1.5–2.2).

## Conclusions

Our results indicate that ongoing HIV replication (suboptimal HIV control) is an important risk factor for TB, independent of CD4 count. Those at highest risk of TB are people from TB-endemic countries. Close monitoring and TB preventive therapy for people with suboptimal HIV control is important.

## Introduction

Tuberculosis (TB) is the leading cause of death from an infectious disease, along with HIV/ AIDS [1]. HIV infection and its resulting immunodeficiency is the most important risk factor for TB, and in many lower-income countries TB is the most common opportunistic infection (OI) [2, 3]. Antiretroviral therapy (ART) has improved the prognosis of HIV infection and markedly reduced the risk of TB [4]. In several observational studies, successful ART has been associated with a lower incidence of TB in low-income countries with high TB burden as well as in affluent countries with low levels of TB transmission [5, 6]. In Western European countries with a low TB incidence, most TB patients are foreign-born, reflecting higher rates of TB infection in their country of birth and subsequent development of active TB in the country of migration [7, 8].

While the risk for TB and other OIs in HIV infection is commonly related to immunodeficiency as measured by circulating CD4 positive T-cells in peripheral blood (CD4 cell count),
people living with HIV at a given CD4 count may have a higher risk for OIs if there is HIV replication as measured by plasma HIV-RNA [9–12]. There is increasing evidence that immune activation due to ongoing HIV replication is an additional important factor of immune disturbance leading to important changes in lymphocyte phenotypes and quality of immune response [13]. In two randomized trials, the early initiation of ART among individuals with high CD4 counts was beneficial regarding the incidence of OIs, including TB [14, 15]. While certain OIs occur almost exclusively in people with very low CD4 counts [16], active TB is observed in every stage of HIV-infection. Even in those with high CD4 counts TB incidence is much higher than in the population of people without HIV [17]. In South Africa, HIV-RNA levels have been shown to be a risk factor for TB independent of CD4 count [11].

The past 15 years have seen a massive scale-up of ART and a decline in AIDS-related deaths worldwide [18], especially with the change in recommendations in 2015 for all people with HIV to receive ART [14, 19]. Despite these positive changes in the public health epidemiology of HIV/TB, understanding the interplay between HIV and TB remains critical for identifying high-risk groups in need of TB preventive therapy (TPT) and for developing optimal clinical and public health strategies. Using the large Collaboration of Observational HIV Epidemiological Research Europe (COHERE) database from 1984–2015, which includes a substantial number of people with both HIV and TB (>5,000), we aimed to delineate the role of current HIV replication as an independent risk factor for TB.

## Methods

### Study setting and study design

COHERE in EuroCoord was a collaboration of over 40 observational cohorts covering 32 European countries within the EuroCoord network of excellence [20]. Each cohort submitted data in a standardized format (the HIV Collaboration Data Exchange Protocol, see http://www.hicdep.org) to coordinating centres at the Copenhagen HIV Programme, Denmark, or the Institut de Santé Publique d'Epidémiologie et de Développement (Bordeaux School of Public Health), Bordeaux, France. The Regional Coordinating Centres ensured adherence to strict data quality assurance guidelines and performed data checks. Submitted data included information on individuals' characteristics (age, gender, geographical origin, and mode of HIV acquisition), use of ART (type of drugs, and dates of start and stop of each drug), dates and results of all CD4 cell counts and plasma HIV-RNA viral load assessments, dates and types of all AIDS-defining events, and information on mortality. Data on testing for latent TB and on TPT were not available. We included people aged 16 years or older with HIV who were enrolled in care between the first quarter of 1983 and the second quarter of 2015 and had no history of previous TB. The selection of patients from 29 COHERE cohorts with TB data is shown in a flow diagram (S1 Fig); four cohorts with too few eligible patients (<350) or lack of specific TB drug/endpoint information were excluded. The data was first accessed for research purposes in June 2019.

### Statistical analysis

The first TB occurrence was defined to be the time of the person's first diagnosis of pulmonary or extrapulmonary tuberculosis. Person-time was defined from enrolment in the respective cohort to first TB occurrence, death, or date of last follow-up visit. A person on ART was defined as a patient taking combined ART at any time during follow-up. Incident TB was defined as any TB diagnosis two months or more after ART start. The diagnosis of TB was made by the treating clinicians according to local diagnostic criteria.
We used Poisson regression models to assess TB incidence per 1,000 person-years and corresponding rate ratios with an offset for the period, stratified by the levels of baseline CD4 cells/µL (0–100, 101–350, >350) and HIV-RNA copies/mL (0–399, 400–10,000, >10,000) and geographical region of birth (Europe, sub-Saharan Africa, Asia, Latin America, North Africa and the Middle East). Models were additionally adjusted for age, gender, geographic region of birth, and mode of HIV acquisition (sex between men and women, sex between men [MSM], injection drug use [IDU], other). We extended regression models including time-updated CD4 cell counts and HIV-RNA levels and using splines to investigate effects in detail. For illustrative purposes, we used the fitted models to predict the incidence for a reference category of men who were aged 35 years, who had acquired HIV following heterosexual sex, and who were on ART.

All analyses were performed in R version 3.2.4 [21].

## Ethics statement

Ethical approval was applied for and granted for the research from the appropriate body in the host country (local ethics committees or institutional review boards) of the cohort contributing the data to COHERE [20]. All cohorts participating in COHERE adhere to local ethical, data management and confidentiality standards.

## Results

Follow-up data for 272,548 people from 25 European cohorts (S1 Table) were included in the analysis, resulting in a total follow-up time of 1,923,441 person-years. The median follow-up time was 5.9 years (interquartile range [IQR] 2.3–10.9). Baseline characteristics (at enrolment into cohort in Europe) of the participants are shown in Table 1: 27% of participants were female, 65% were born in Europe (including Eastern Europe), and 46% were on ART. The median CD4 cell counts was 355 cells/µL at baseline, and 13% had a HIV-RNA levels below 400 copies/mL. There were 5,956 first episodes of TB over follow-up, resulting in an overall TB incidence of 3.1 per 1,000 person-years (95% confidence interval [CI] 3.0–3.2). TB occurred at a median of 1.5 years (IQR 0.2–4.5 years) after enrolment in the respective cohort.

In the Poisson regression model stratifying by CD4 count and HIV-RNA levels (Table 1), TB incidence was significantly associated with the following baseline characteristics: gender, HIV acquisition mode other than sex between men, participant geographic origin (particularly in those born in Africa, Asia, and Latin America), CD4 cell count <350 vs. ≥350, HIV-RNA ≥400 vs. <400 copies/ml, and not being on ART at baseline (Table 1). In addition, the incidence rate ratio for people born in Asia and sub-Saharan Africa compared to those from Europe were 2.5 (95% CI 2.0–3.0) and 2.4 (95% CI 2.2–2.6), respectively. More generally, the incidence rate ratio of those of non-European compared to European origin was 1.8 (95% CI 1.5–2.2). There was no significant interaction between geographic origin and HIV-RNA or CD4 count (each p = 0.34).

Time-updated analyses of the CD4 cell count and HIV-RNA levels, fixed at different CD4 levels for a reference participant category, showed that the association between HIV-RNA and TB incidence was independent of CD4 cell counts (Fig 1). The trajectory of the HIV-RNA curves was similar at all CD4 cell levels, with slopes becoming steeper at levels above 10,000 HIV-RNA copies/mL and reaching four times higher incidence levels than those with HIV-RNA levels below 400 copies/mL. A similar association was observed in people from all geographic regions (Fig 2). In all CD4 count and viral load categories, the incidence of TB was highest among people of Asian and sub-Saharan African origin (Fig 2): 81/1,000 and 82/1,000 person-years, respectively, for the highest risk category. Time-updated CD4 cell counts (cells/µL)
<table><caption>Table 1. Individual characteristics (at enrolment into cohort) of 272,548 people with HIV from 25 European cohorts, with and without tuberculosis (TB) after enrolment.</caption><thead><tr><th>Characteristic n (%)</th><th>Total in study</th><th>People with TB</th><th>People without TB</th><th>IRR (95% CI)</th><th>p-value</th></tr></thead><tbody><tr><td>Number of people</td><td>272,548</td><td>5,956 (2.2)</td><td>266,592 (97.8)</td><td></td><td></td></tr><tr><td>Time period</td><td></td><td></td><td></td><td></td><td>&lt;0.001</td></tr><tr><td>1984–1995</td><td>24,165 (8.9)</td><td>1,001 (4.1)</td><td>23,164 (95.9)</td><td></td><td></td></tr><tr><td>1996–2015</td><td>248,383 (91.1)</td><td>4,955 (2.0)</td><td>24,3428 (98.0)</td><td></td><td></td></tr><tr><td>Female gender</td><td>73,370 (26.9)</td><td>2,021 (33.9)</td><td>71,349 (26.8)</td><td>0.80 (0.75–0.86)</td><td>&lt;0.001</td></tr><tr><td>Age, years, median (IQR)</td><td>36.0 (30.1–43.2)</td><td>34.9 (29.8–41.2)</td><td>36.0 (30.1–43.2)</td><td>0.99 (0.99–0.99)</td><td>&lt;0.001</td></tr><tr><td>Mode of HIV acquisition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sex between men and women</td><td>99,893 (36.7)</td><td>2,914 (48.9)</td><td>96,979 (36.4)</td><td>1.0</td><td></td></tr><tr><td>Sex between men</td><td>113,715 (41.7)</td><td>1,174 (19.7)</td><td>112,541 (42.2)</td><td>0.41 (0.37–0.44)</td><td>&lt;0.001</td></tr><tr><td>Injection drug use</td><td>31,823 (11.7)</td><td>1,245 (20.9)</td><td>30,578 (11.5)</td><td>1.03 (0.95–1.12)</td><td>0.46</td></tr><tr><td>Other</td><td>9,035 (3.3)</td><td>251 (4.2)</td><td>8,784 (3.3)</td><td>0.77 (0.67–0.89)</td><td>&lt;0.001</td></tr><tr><td>Missing, n (%)</td><td>18,082 (6.6)</td><td>372 (6.2)</td><td>17,710 (6.6)</td><td>-</td><td></td></tr><tr><td>CD4, cells/µL, median (IQR)</td><td>355 (193–540)</td><td>243.0 (100–414)</td><td>358 (196–542)</td><td></td><td>&lt;0.001</td></tr><tr><td>&lt;100</td><td>33,530 (12.3%)</td><td>1,254 (21.1%)</td><td>32,376 (12.1%)</td><td>1.0</td><td></td></tr><tr><td>100–350</td><td>86,109 (31.6%)</td><td>2,102 (35.3%)</td><td>83,914 (31.5%)</td><td>0.31 (0.29–0.32)</td><td>&lt;0.001</td></tr><tr><td>&gt;350</td><td>122,472 (44.9%)</td><td>1,653 (27.8%)</td><td>120,819 (45.3%)</td><td>0.11 (0.10–0.12)</td><td>&lt;0.001</td></tr><tr><td>Missing, n (%)</td><td>30,530 (11.2)</td><td>947 (15.9)</td><td>29,583 (11.1)</td><td>-</td><td></td></tr><tr><td>HIV viral loads, log<sub>10</sub> copies/mL, median (IQR)</td><td>4.3 (3.1, 5.0)</td><td>4.8 (4.0, 5.3)</td><td>4.3 (3.1, 5.0)</td><td></td><td>&lt;0.001</td></tr><tr><td>HIV viral loads, copies/mL</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>&lt;400</td><td>36,266 (13.3)</td><td>304 (5.1)</td><td>35,962 (13.5)</td><td>1.0</td><td></td></tr><tr><td>400–10,000</td><td>45,532 (16.7)</td><td>594 (10.0)</td><td>44,938 (16.9)</td><td>1.69 (1.54–1.84)</td><td>&lt;0.001</td></tr><tr><td>&gt;10,000</td><td>120,052 (44.0)</td><td>2,641 (44.3)</td><td>117,411 (44.0)</td><td>3.8 (3.51–4.08)</td><td>&lt;0.001</td></tr><tr><td>Missing, n (%)</td><td>70,738 (25.9)</td><td>2,417 (40.6)</td><td>68,281 (25.6)</td><td>-</td><td></td></tr><tr><td>Region of origin</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Europe</td><td>176,088 (64.6)</td><td>3,263 (54.8)</td><td>172,825 (64.8)</td><td>1.0</td><td></td></tr><tr><td>Africa</td><td>26,946 (9.9)</td><td>1,240 (20.8)</td><td>25,706 (9.6)</td><td>2.43 (2.24–2.64)</td><td>&lt;0.001</td></tr><tr><td>Asia</td><td>3,464 (1.3)</td><td>129 (2.2)</td><td>3,335 (1.3)</td><td>2.45 (2.00–2.99)</td><td>&lt;0.001</td></tr><tr><td>Latin America</td><td>9,681 (3.6)</td><td>248 (4.2)</td><td>9,433 (3.5)</td><td>1.74 (1.50–2.02)</td><td>&lt;0.001</td></tr><tr><td>N Africa/Middle East</td><td>4,119 (1.5)</td><td>129 (2.2)</td><td>3,990 (1.5)</td><td>1.40 (1.13–1.72)</td><td>0.002</td></tr><tr><td>Other or unknown</td><td>52,250 (19.2)</td><td>947 (15.9)</td><td>51,303 (19.2)</td><td>1.35 (1.24–1.47)</td><td>&lt;0.001</td></tr><tr><td>On ART</td><td>123,322 (45.2)</td><td>2,027 (34)</td><td>121,295 (45.5)</td><td>0.76 (0.72–0.81)</td><td>&lt;0.001</td></tr><tr><td>Follow-up time, years, median (IQR)</td><td>5.9 (2.3–10.9)</td><td>1.5 (0.2–4.5)</td><td>6.1 (2.4–11.0)</td><td>-</td><td></td></tr></tbody></table>

ART, antiretroviral therapy; CI, confidence interval; IRR, incidence rate ratio

https://doi.org/10.1371/journal.pone.0312035.t001

stratified by geographic origin showed similar curves in all regions, but people originating from Europe had lower TB incidence at all CD4 cell count levels compared to those from all other regions (S2 Fig).

Discussion

We analyzed data from almost 300,000 people with HIV enrolled into care in 25 large HIV cohorts in Europe from 1983 to 2015. Overall TB incidence was at 3.10 per 1,000 person-years. We found that individuals with increasing HIV replication, as determined by plasma HIV-RNA levels, had an increasing risk of TB, independent of CD4 cell count and all other variables. The risk of TB was particularly high in people born in Africa and Asia, reflecting the higher prevalence of TB in these regions.
<figure><img src="image_5.png" /><figcaption>**Fig 1. Tuberculosis (TB) incidence rate per 1,000 person-years for a reference population estimated at any given HIV-RNA levels, based on time-updated measurements and displayed at different CD4 levels.** Patient reference category: heterosexual, male, 35 years old, on ART, born in Europe. Shaded areas corresponding to 95% confidence intervals.</figcaption></figure>

https://doi.org/10.1371/journal.pone.0312035.g001

The large collaborative HIV cohort dataset in Europe allowed us to show that HIV viral load provides useful information for predicting higher risk of TB after ART initiation, independent of CD4 cell count. This finding might be explained by the fact that HIV replication itself is associated with a disturbed immune system and impaired protection against progression from infection to disease [13]. Underlying immunological processes include increased cell turnover, cell activation, and cytokine release [11, 13]. This is also evidenced by a decreased immune response to vaccines such as yellow fever and influenza in patients with ongoing HIV replication with high HIV-RNA levels [22, 23]. We have shown that detectable HIV-RNA, which indicates ongoing HIV replication, is a critical laboratory parameter for identifying populations at higher risk for TB, along with CD4 count and place of birth. All current guidelines [14, 19] recommend that all people with HIV receive ART, regardless of their CD4 cell count at the time of diagnosis. However, this was not the case during the period analyzed in this study. In Europe, widespread access to effective combination ART began in 1996 and has dramatically reduced the number of deaths among people living with HIV [20, 24].

In this large European dataset with a diverse migrant population, we observed that TB risk depends on a person's geographic origin. In Europe, the overall incidence of TB has been decreasing since 2000, but notification rates vary across the region, with the highest rates reported in Eastern Europe [25]. The same decline has been found across European HIV cohorts and in the Swiss HIV Cohort Study [26, 27]. In contrast, some European countries have reported an increase in TB incidence among people with HIV because of increasing
<figure><img src="image_6.png" /><figcaption>**Fig 2.** TB incidence stratified by CD4 cell count (cells/µL), HIV-RNA viral load (copies/mL), and geographic origin for a reference population. TB incidence rates per 1,000 person-years estimated from fitted Poisson regression models. Patient reference category: 35 years of age, male, heterosexual, on ART.</figcaption></figure>

https://doi.org/10.1371/journal.pone.0312035.g002

numbers of migrants from lower-income countries with high TB incidence and possibly because of delayed access to care [28–30]. The current war in Ukraine, with internal displacement of citizens and migration of refugees, may further increase the burden of TB in Europe, particularly drug-resistant TB [31]. Indeed, migrants to Europe with HIV/TB co-infection may not receive optimal care and follow-up in low-incidence countries [32]. Differences also exist between Western and Eastern Europe in the delivery of TB and HIV care, including integration of TB and HIV care and access to MDR-TB drugs [33]. In general, risk factors for TB in people with HIV include not being on ART, the origin of the person (e.g., sub-Saharan Africa and Eastern Europe), but also low CD4 cell counts and higher HIV viral loads [30]. However, the latter study did not examine the possibility of there being an interaction between the CD4 cell count and HIV viral load for the risk of TB.

People with HIV who have detectable HIV viral loads at any time are at increased risk of active TB by reactivation of latent TB, reinfection, or rapid progression after recent infection, regardless of their CD4 cell counts. Therefore, in addition to early initiation of ART or optimization of ART, these individuals may particularly benefit from the administration of TPT to reduce the risk of TB in persons with latent TB, especially in migrant populations originating from TB-endemic countries and possibly higher exposure to TB. Prevention of active TB disease by TPT is a critical component of the WHO End TB Strategy [34] and has been shown to be highly effective in the Western European setting [12]. WHO recommendations for settings
with a high burden of TB and HIV state that adults, adolescents, children, and infants with
HIV should receive TPT, irrespective of the degree of immunosuppression and even if latent
TB infection testing is unavailable [35]. The positive impact of ART on reducing the incidence
of TB in people with HIV has been well established [6]. In any case, people at high risk identi-
fied in our study should be considered for latent TB screening and TPT if active TB has been
excluded and should be closely monitored during HIV care to reduce the risk of treatment
interruptions and eventually ensure early diagnosis of TB.

A limitation of our study is that the data date back many years, spanning 1983–2015. How-
ever, the current epidemiology of HIV/TB in Europe no longer allows for detailed and strati-
fied analyses, as only a few new TB cases have been diagnosed in recent years [27, 28] and
most of these are in people with a late HIV diagnosis [36]. While this changing epidemiology
is welcome, it does mean that only these older data allow detailed analyses of risk factors for
TB based on CD4 cell counts, HIV RNA viral loads, and person’s birth origin. Such analyses
provide valuable information for current management and monitoring in high-risk popula-
tions, particularly in the context of ongoing wars and immigration. Other limitations include
the limited number of people with HIV followed in Eastern Europe, which has a different TB
epidemiology [37], and that there may be residual confounding (homelessness, instable social
conditions, alcohol use) that was not captured in our dataset. An important strength of the
study is that the data come from a well-established, large-scale, collaborative HIV cohort proj-
ect that has collected high-quality data with little missing information [20].

In conclusion, understanding the interplay between HIV and TB is paramount to develop-
ing clinical management and effective public health strategies to reduce the burden of TB in
people with HIV. Our results show that higher levels of ongoing HIV replication are associated
with a higher risk of TB, regardless of CD4 cell count. Individuals with latent TB, often origi-
nating from countries at high risk of TB infection, particularly require effective ART, close
clinical monitoring to ensure undetectable HIV-RNA levels, and a low threshold for adminis-
tration of TPT once active TB has been excluded.

**Supporting information**

S1 Table. Breakdown of participants in the study by cohort.
(PDF)

S1 Fig. Selection of the study population.
(PDF)

S2 Fig. TB incidence rate per 1,000 person-years for a reference population, based on time-
updated measurements and stratified by CD4 counts (reference: 35 years of age, male, het-
erosexual, on ART). A: All regions are shown unless the region was unknown. B: Only sub-
Saharan Africa, Asia, and Europe are shown for clarity.
(PDF)

**Acknowledgments**

We thank all individuals whose data were used in this study. We also would like to thank all
who contributed to recording and entering data and preparing and sending it to the COHERE
collaboration.

**Steering Committee—Contributing Cohorts:** Ali Judd (AALPHI), Robert Zangerle (AHIVCOS), Giota Touloumi (AMACS), Josiane Warszawski (ANRS CO1 EPF/ANRS CO11 OBSERVATOIRE EPF), Laurence Meyer (ANRS CO2 SEROCO), François Dabis (ANRS CO3 AQUITAINE), Murielle Mary Krause (ANRS CO4 FHDH), Jade Ghosn (ANRS CO6
PRIMO), Catherine Leport (ANRS CO8 COPILOTE), Linda Wittkop (ANRS CO13 HEPA-VIH), Peter Reiss (ATHENA), Ferdinand Wit (ATHENA), Maria Prins (CASCADE), Heiner Bucher (CASCADE), Diana Gibb (CHIPS), Gerd Fätkenheuer (Cologne-Bonn), Julia Del Amo (CoRIS), Niels Obel (Danish HIV Cohort), Claire Thorne (ECS, NSHPC), Amanda Mocroft (EuroSIDA), Ole Kirk (EuroSIDA), Christoph Stephan (Frankfurt), Santiago Pérez-Hoyos (GEMES-Haemo), Osamah Hamouda (German ClinSurv), Barbara Bartmeyer (German ClinSurv), Nikoloz Chkhartishvili (Georgian National HIV/AIDS), Antoni Noguera-Julian (CORISPE-cat), Andrea Antinori (ICC), Antonella d'Arminio Monforte (ICONA), Norbert Brockmeyer (KOMPNET), Luis Prieto (Madrid PMTCT Cohort), Pablo Rojo Conejo (CORISPES-Madrid), Antoni Soriano-Arandes (NENEXP), Manuel Battegay (SHCS), Roger Kouyos (SHCS), Cristina Mussini (Modena Cohort), Jordi Casabona (PISCIS), Jose M. Miró (PISCIS), Antonella Castagna (San Raffaele), Deborah_Konopnick (St. Pierre Cohort), Tessa Goetghebuer (St Pierre Paediatric Cohort), Anders Sönnerborg (Swedish InfCare), Carlo Torti (The Italian Master Cohort), Caroline Sabin (UK CHIC), Ramon Teira (VACH), Myriam Garido (VACH). David Haerry (European AIDS Treatment Group)

**Executive Committee:** Stéphane de Wit (Chair, St. Pierre University Hospital), Jose Mª Miró (PISCIS), Dominique Costagliola (FHDH), Antonella d'Arminio-Monforte (ICONA), Antonella Castagna (San Raffaele), Julia del Amo (CoRIS), Amanda Mocroft (EuroSida), Dorthe Raben (Head, Copenhagen Regional Coordinating Centre), Geneviève Chêne (Head, Bordeaux Regional Coordinating Centre). Paediatric Cohort Representatives: Ali Judd, Pablo Rojo Conejo.

**Regional Coordinating Centres:** Bordeaux RCC: Diana Barger, Christine Schwimmer, Monique Termote, Linda Wittkop; Copenhagen RCC: Casper M. Frederiksen, Dorthe Raben, Rikke Salbøl Brandt.

**Project Leads and Statisticians:** Juan Berenguer, Julia Bohlius, Vincent Bouteloup, Heiner Bucher, Alessandro Cozzi-Lepri, François Dabis, Antonella d'Arminio Monforte, Mary-Anne Davies, Julia del Amo, Maria Dorrucci, David Dunn, Matthias Egger, Hansjakob Furrer, Marguerite Guiguet, Sophie Grabar, Ali Judd, Ole Kirk, Olivier Lambotte, Valériane Leroy, Sara Lodi, Sophie Matheron, Laurence Meyer, Jose Mª Miró, Amanda Mocroft, Susana Monge, Fumiyo Nakagawa, Roger Paredes, Andrew Phillips, Massimo Puoti, Eliane Rohner, Michael Schomaker, Colette Smit, Jonathan Sterne, Rodolphe Thiebaut, Claire Thorne, Carlo Torti, Marc van der Valk, Linda Wittkop.

## Author Contributions

**Conceptualization:** Andrew Atkinson, David Kraus, Marcel Zwahlen, Matthias Egger, Hansjakob Furrer, Lukas Fenner.

**Data curation:** Andrew Atkinson, David Kraus, Jose M. Miro, Peter Reiss, Ole Kirk, Cristina Mussini, Philippe Morlat, Daria Podlekareva, Alison D. Grant, Caroline Sabin, Marc van der Valk, Vincent Le Moing, Laurence Meyer, Remonie Seng, Antonella Castagna, Niels Obel, Anastasia Antoniadou, Dominique Salmon, Stephane de Wit, Hansjakob Furrer.

**Formal analysis:** Andrew Atkinson, David Kraus, Nicolas Banholzer.

**Funding acquisition:** Marcel Zwahlen, Hansjakob Furrer, Lukas Fenner.

**Investigation:** Andrew Atkinson, Lukas Fenner.

**Methodology:** Andrew Atkinson, David Kraus, Marcel Zwahlen, Lukas Fenner.

**Resources:** Jose M. Miro, Peter Reiss, Ole Kirk, Cristina Mussini, Philippe Morlat, Daria Podlekareva, Alison D. Grant, Caroline Sabin, Marc van der Valk, Vincent Le Moing,
Laurence Meyer, Remonie Seng, Antonella Castagna, Niels Obel, Anastasia Antoniadou, Dominique Salmon, Matthias Egger, Stephane de Wit, Hansjakob Furrer.

**Supervision:** Hansjakob Furrer, Lukas Fenner.

**Visualization:** Andrew Atkinson, David Kraus, Nicolas Banholzer.

**Writing – original draft:** Andrew Atkinson, David Kraus, Nicolas Banholzer, Hansjakob Furrer, Lukas Fenner.

**Writing – review & editing:** Andrew Atkinson, David Kraus, Nicolas Banholzer, Jose M. Miro, Peter Reiss, Ole Kirk, Cristina Mussini, Philippe Morlat, Daria Podlekareva, Alison D. Grant, Caroline Sabin, Marc van der Valk, Vincent Le Moing, Laurence Meyer, Remonie Seng, Antonella Castagna, Niels Obel, Anastasia Antoniadou, Dominique Salmon, Marcel Zwahlen, Matthias Egger, Stephane de Wit, Hansjakob Furrer.

## References

1. World Health Organization. Global Tuberculosis Report 2022. [cited 11 Apr 2023]. Available: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.

2. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003; 36: 652–662. CID21096 [pii]; https://doi.org/10.1086/367655 PMID: 12594648

3. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis. 2002; 34: 1251–1258. CID011234 [pii]; https://doi.org/10.1086/339540 PMID: 11941552

4. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999; 282: 2220–2226. https://doi.org/10.1001/jama.282.23.2220 PMID: 10605973

5. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9: e1001270. https://doi.org/10.1371/journal.pmed.1001270 PMID: 22911011

6. del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, et al. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012; 54: 1364–1372. https://doi.org/10.1093/cid/cis203 PMID: 22460971

7. Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, et al. *Mycobacterium tuberculosis* transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol. 2012; 50: 388–395.

8. Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, et al. Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country. J Clin Microbiol. 2016; 54: 1862–1870. https://doi.org/10.1128/JCM.00126-16 PMID: 27194683

9. Kaplan JE, Hanson DL, Jones JL, Dworkin MS. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS. 2001; 15: 1831–1836. https://doi.org/10.1097/00002030-200109280-00012 PMID: 11579245

10. Atkinson A, Miro JM, Mocroft A, Reiss P, Kirk O, Morlat P, et al. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed vir-aemia and a CD4 cell count greater than 100 cells/µL. J Int AIDS Soc. 2021; 24: e25726. https://doi.org/10.1002/jia2.25726 PMID: 34118121

11. Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, et al. HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. J Int AIDS Soc. 2017;20. https://doi.org/10.7448/IAS.20.1.21327 PMID: 28691438

12. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007; 44: 94–102. https://doi.org/10.1086/510080 PMID: 17143823

13. Moir S, Chun T-W, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011; 6: 223–248. https://doi.org/10.1146/annurev-pathol-011110-130254 PMID: 21034222

14. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund Bet al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373: 795–807. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873
15. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373: 808–822. https://doi.org/10.1056/NEJMoa1507198 PMID: 26193126

16. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996; 124: 633–42. https://doi.org/10.7326/0003-4819-124-7-199604010-00003 PMID: 8607591

17. Girardi E, Sabin CA, D'Arminio MA, Hogg B, Phillips AN, Gill MJ, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005; 41: 1772–1782. CID37465 [pii]; https://doi.org/10.1086/498315 PMID: 16288403

18. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016; 375: 830–839. https://doi.org/10.1056/NEJMoa1600693 PMID: 27424812

19. Consolidated guidelines on HIV, viral hepatitis and STI for key populations—2022. [cited 19 Jul 2023]. Available: https://www.who.int/publications-detail-redirect/9789240052390

20. Chêne G, Phillips A, Costagliola D, Sterne JA, Furrer H, del Amo J, et al. Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Int J Epidemiol. 2017; 46: 797–797n. https://doi.org/10.1093/ije/dyw211 PMID: 27864413

21. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2022. Available: https://www.R-project.org/.

22. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009; 48: 1402–1412. https://doi.org/10.1086/598193 PMID: 19361304

23. Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009; 48: 659–666. https://doi.org/10.1086/597006 PMID: 19191654

24. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. The Lancet. 2003; 362: 22–29. https://doi.org/10.1016/S0140-6736(03)13802-0 PMID: 12853195

25. European Centre for Disease Prevention and Control., World Health Organization. Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2022: 2020 data. LU: Publications Office; 2022. Available: https://data.europa.eu/doi/10.2900/488579.

26. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, et al. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. Aids. 2011;25. https://doi.org/10.1097/QAD.0b013e328348fafd PMID: 21610489

27. Zeeb M, Tepekule B, Kusejko K, Reiber C, Kälin M, Bartl L, et al. Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in Switzerland. Clin Infect Dis. 2023; ciad330. https://doi.org/10.1093/cid/ciad330 PMID: 37257071

28. van Halsema CL, Okhai H, Hill T, Sabin CA, for the UK Collaborative HIV Cohort (UK CHIC). Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. AIDS. 2020; 34: 1813. https://doi.org/10.1097/QAD.0000000000002599 PMID: 32501837

29. Tavares AM, Fronteira I, Couto I, Machado D, Viveiros M, Abecasis AB, et al. HIV and tuberculosis coinfection among migrants in Europe: A systematic review on the prevalence, incidence and mortality. PLOS ONE. 2017; 12: e0185526. https://doi.org/10.1371/journal.pone.0185526 PMID: 28957400

30. Abgrall S, Del GP, Melica G, Costagliola D. HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. Aids. 2010; 24: 763–771. https://doi.org/10.1097/QAD.0b013e3283366747 PMID: 20087155

31. Dahl V, Migliori GB, Lange C, Wejse C. War in Ukraine: an immense threat to the fight against tuberculosis. Eur Respir J. 2022;59. https://doi.org/10.1183/13993003.00493–2022

32. Fenner L, Gagneux S, Janssens JP, Fehr J, Cavassini M, Hoffmann M, et al. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. PLoS One. 2012; 7(3): e34186; https://doi.org/10.1371/journal.pone.0034186 PMID: 22479556

33. Bentzon A, Panteleev A, Mitsura V, Borodulina E, Skrahina A, Denisova E, et al. Healthcare delivery for HIV-positive people with tuberculosis in Europe. HIV Med. 2021; 22: 283–293. https://doi.org/10.1111/hiv.13016 PMID: 33215809

34. World Health Organization. The End TB Strategy; Global strategy and targets for tuberculosis prevention, care and control after 2015a. World Health Organ Doc. 2014.

35. World Health Organization. WHO operational handbook on tuberculosis. Module 1: Prevention—Tuberculosis preventive treatment. World Health Organ. 2021.
36. Girardi E, Caro-Vega Y, Cozzi-Lepri A, Musaazi J, Carriquiry G, Castelnuovo B, et al. The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis: a 5-year estimate using real-world data. AIDS. 2022; 36: 2005–2013. https://doi.org/10.1097/QAD.0000000000003321 PMID: 35848588

37. Podlekareva DN, Efsen AMW, Schultze A, Post FA, Skrahina AM, Pantelev A, et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV. 2016; 3: e120–131. https://doi.org/10.1016/S2352-3018(15)00252-0 PMID: 26939735